References
- Tambuyer E, Vandendriessche B, Austin CP, et al. Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. Nat Rev Drug Discov. February 2019;19:93–111.
- Orphan medicinal products Paolo Tomasi. 2019 Sept 10.
- Loorand-Stiver L, Cowling T, Perras C. Drugs for rare diseases: evolving trends in regulatory and health technology assessment perspectives. [cited 2019 Aug 16]. Available from: https://www.cadth.ca/drugs-rare-diseases-evolving-trends-regulatory-and-health-technology-assessment-perspectives
- Westermark K, Westermark K, Holm BB, et al. European regulation on orphan medicinal products: 10years of experience and future perspectives. Nat Rev Drug Discov. 2011 May;10:341–349.
- Kakkis E, O’Donovan M, Cox G, et al. Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints. Orphanet J Rare Dis. 2015;10:16.
- EMA Orphan medicines Figures. [cited 2019 Aug 16]. Available from: https://www.ema.europa.eu/en/documents/other/orphan-medicines-figures-2000-2018_en.pdf
- Ponzano S, Nigrelli G, Fregonese L, et al. A European regulatory perspective on cystic fibrosis: current treatments, trends in drug development and translational challenges for CFTR modulators. Eur Respir Rev. 2018;27:1–11.
- Tsigkos S, Hofer MP, Sheean ME, et al. Establishing rarity in the context of orphan medicinal product designation in the European Union. Drug Discov Today. 2017 June;23(3):681–686.
- Harari S. Why we should care about ultra-rare disease. Eur Respir Rev. 2016;25:101–103.
- Pinto D, Martin D, Chenhall R, et al. The involvement of patient organisations in rare disease research: a mixed method study in Australia. Orphanet J Rare Dis. 2016;11:2.
- Gorman G, Chinnery PF, DiMauro S, et al. Mitochondrial diseases. Nat Rev Dis Primers. 2016;2:Article number: 16080.
- Sobrido M, Bauer P, de Koning T, et al. Recommendations for patient screening in ultra-rare inherited metabolic diseases: what have we learned from Niemann-Pick disease type C? Orphanet J Rare Dis. 2019;14:20.
- Groen E, Talbot K, Gillingwater TH, et al. Advances in therapy for spinal muscular atrophy: promises and challenges. Nat Rev Neurol. 2018;14:214–224.
- Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378:1811–1823.
- Guideline on the format and content of applications for designation as orphan medicinal products and on the transfer of designations from one sponsor to another. 2014 Mar 27.